Live Breaking News & Updates on Cooperation Pharmaceutique Francaise

3 Min Read
PARIS (Reuters) - European private equity firm Charterhouse Capital Partners said on Friday it had entered exclusive talks to sell a majority stake in French drugmaker Cooperation Pharmaceutique Francaise, known as Cooper, to CVC Capital Partners.
Slideshow ( 2 images )
The deal values the Paris-based firm at about 2.2 billion euros ($2.6 billion) and will see Charterhouse reinvesting in the business after having more than doubled its size since taking control in 2016, a source familiar with the matter told Reuters.
Following the deal and reinvestment, Charterhouse will own about 20% of the firm, the source said.
The London-based private equity firm is expected to return more than 1.2 billion euros to its investors when the deal completes, the source said. ....

France General , City Of , United Kingdom , Pharmaceutique Francaise , Vincent Pautet , Jan Harvey , Jason Neely , Pamela Barbaglia , Freshfields Bruckhaus Deringer , Dominique Vidalon , Thomson Reuters Trust Principles , Charterhouse Capital Partners , Cooperation Pharmaceutique Francaise , Thomson Reuters Trust , Banking Amp Investment Services Trbc Level 2 , Company News , Generic Pharmaceuticals Trbc Level 5 , Financials Legacy , Financials Trbc Level 1 , Health Medicine , Healthcare Trbc Level 1 , Uk Investment Trusts Trbc Level 5 , Mergers Acquisitions Takeovers , Pharmaceuticals Trbc Level 4 , Pharmaceuticals Nec Trbc Level 5 , Private Equity Trbc Level 5 ,